The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential data.
This rejection became public following a official document from December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesperson has since clarified that the United States was demanding access to health data for scientific study and profit but was unwilling to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further dialogue to find a agreement agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Background
This rejection follows a similar case in neighbouring Kenya, where a high court suspended a related deal with the US following legal challenges were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen African countries have to date signed these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our population should a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This system is designed to ensure that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome continued dialogue with our US partners on how future collaboration could be arranged in a way that honours the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but urged that talks need to persist considering much of the nation's HIV programmes depended on foreign aid.
"Where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group commented.
The situation underscores the ongoing challenges between receiving crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.